Clinical outcomes improved and reduced markers of inflammation were seen after administration of acalabrutinib (Calquence) for patients with severe coronavirus disease 2019 (COVID-19), according to results of a study published in Science Immunology.
More, oxygen requirements among the patients decreased, with ongoing global trials in motion to confirm the findings.
“The science supporting investigation of the use of Calquence in patients with severe COVID-19 is strong,” José Baselga, executive vice president, oncology R&D, said in a press release. “The encouraging preliminary data in this case series has informed the initiation of global phase 2 trials, notably the CALAVI program. We look forward to completing recruitment and obtaining data in these trials as soon as possible to further our understanding of what this potential treatment could mean for patients.”